230 related articles for article (PubMed ID: 26046338)
21. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
Thompson PA; Buckley PF; Meltzer HY
J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
[TBL] [Abstract][Full Text] [Related]
22. Linking the PANSS, BPRS, and CGI: clinical implications.
Leucht S; Kane JM; Etschel E; Kissling W; Hamann J; Engel RR
Neuropsychopharmacology; 2006 Oct; 31(10):2318-25. PubMed ID: 16823384
[TBL] [Abstract][Full Text] [Related]
23. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
[TBL] [Abstract][Full Text] [Related]
24. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
[TBL] [Abstract][Full Text] [Related]
25. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
Haddad PM; Correll CU
Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
27. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
28. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
[TBL] [Abstract][Full Text] [Related]
29. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Tollefson GD; Andersen SW
J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
[TBL] [Abstract][Full Text] [Related]
30. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
31. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
32. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
[TBL] [Abstract][Full Text] [Related]
33. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
34. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
35. Optimizing early prediction for antipsychotic response in schizophrenia.
Chang YC; Lane HY; Yang KH; Huang CL
J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
[TBL] [Abstract][Full Text] [Related]
36. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen YS; Lane HY
J Clin Psychiatry; 2007 Oct; 68(10):1522-7. PubMed ID: 17960966
[TBL] [Abstract][Full Text] [Related]
37. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
39. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]